These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37036756)

  • 1. A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
    Spencer KR; Portal DE; Aisner J; Stein MN; Malhotra J; Shih W; Chan N; Silk AW; Ganesan S; Goodin S; Gounder M; Lin H; Li J; Cerchio R; Marinaro C; Chen S; Mehnert JM
    Oncotarget; 2023 Apr; 14():302-315. PubMed ID: 37036756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
    Siu LL; Awada A; Takimoto CH; Piccart M; Schwartz B; Giannaris T; Lathia C; Petrenciuc O; Moore MJ
    Clin Cancer Res; 2006 Jan; 12(1):144-51. PubMed ID: 16397036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
    Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
    Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
    Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
    Cai Z; Wang C; Liu P; Shen P; Han Y; Liu N
    Phytomedicine; 2016 Nov; 23(12):1295-1300. PubMed ID: 27765348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of pemetrexed with sorafenib in advanced solid tumors.
    Poklepovic A; Gordon S; Shafer DA; Roberts JD; Bose P; Geyer CE; McGuire WP; Tombes MB; Shrader E; Strickler K; Quigley M; Wan W; Kmieciak M; Massey HD; Booth L; Moran RG; Dent P
    Oncotarget; 2016 Jul; 7(27):42625-42638. PubMed ID: 27213589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
    Dasari A; Gore L; Messersmith WA; Diab S; Jimeno A; Weekes CD; Lewis KD; Drabkin HA; Flaig TW; Camidge DR
    Invest New Drugs; 2013 Feb; 31(1):115-25. PubMed ID: 22415798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
    Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
    Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
    LoConte NK; Holen KD; Schelman WR; Mulkerin DL; Deming DA; Hernan HR; Traynor AM; Goggins T; Groteluschen D; Oettel K; Robinson E; Lubner SJ
    Invest New Drugs; 2013 Aug; 31(4):943-8. PubMed ID: 23263993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
    Kupsch P; Henning BF; Passarge K; Richly H; Wiesemann K; Hilger RA; Scheulen ME; Christensen O; Brendel E; Schwartz B; Hofstra E; Voigtmann R; Seeber S; Strumberg D
    Clin Colorectal Cancer; 2005 Sep; 5(3):188-96. PubMed ID: 16197622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
    Puzanov I; Sosman J; Santoro A; Saif MW; Goff L; Dy GK; Zucali P; Means-Powell JA; Ma WW; Simonelli M; Martell R; Chai F; Lamar M; Savage RE; Schwartz B; Adjei AA
    Invest New Drugs; 2015 Feb; 33(1):159-68. PubMed ID: 25294187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
    Kumar SK; Jett J; Marks R; Richardson R; Quevedo F; Moynihan T; Croghan G; Markovic SN; Bible KC; Qin R; Tan A; Molina J; Kaufmann SH; Erlichman C; Adjei AA
    Invest New Drugs; 2013 Oct; 31(5):1201-6. PubMed ID: 23887852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
    J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
    Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
    Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
    Richly H; Henning BF; Kupsch P; Passarge K; Grubert M; Hilger RA; Christensen O; Brendel E; Schwartz B; Ludwig M; Flashar C; Voigtmann R; Scheulen ME; Seeber S; Strumberg D
    Ann Oncol; 2006 May; 17(5):866-73. PubMed ID: 16500908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
    Widemann BC; Kim A; Fox E; Baruchel S; Adamson PC; Ingle AM; Glade Bender J; Burke M; Weigel B; Stempak D; Balis FM; Blaney SM
    Clin Cancer Res; 2012 Nov; 18(21):6011-22. PubMed ID: 22962440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
    Emiloju OE; Yin J; Koubek E; Reid JM; Borad MJ; Lou Y; Seetharam M; Edelman MJ; Sausville EA; Jiang Y; Kaseb AO; Posey JA; Davis SL; Gores GJ; Roberts LR; Takebe N; Schwartz GK; Hendrickson AEW; Kaufmann SH; Adjei AA; Hubbard JM; Costello BA
    Invest New Drugs; 2024 Feb; 42(1):127-135. PubMed ID: 38270822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
    Toffalorio F; Spitaleri G; Catania C; Dal Zotto L; Noberasco C; Delmonte A; Santarpia M; Vecchio F; Brunelli V; Rampinelli C; Barberis M; Fumagalli C; Zucchetti M; Zangarini M; Diena T; Danesi R; de Braud F; De Pas T
    Oncologist; 2014 Apr; 19(4):344-5. PubMed ID: 24674875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.